At the time of my last article in April, VKTX reported data from a study of four weeks treatment with oral VK2735 in obese subjects, but only up to 40 mg (3.7% placebo-adjusted weight loss).
Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...
Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...
In the MAD trial, oral VK2735 also demonstrated encouraging safety and tolerability through 28 days of once-daily dosing at doses up to and including 100 mg. The majority (99%) of observed ...
Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...
A phase I study of an oral version of the drug also showed promising results. In the 28-day study, 45 people were randomly assigned to take one of five VK2735 doses (2.5 mg, 5 mg, 10 mg ...
CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide (2.4 mg) and semaglutide (2. ... (CDMO), to produce its obesity drug VK2735 (both subcutaneous and oral).
Zacks Investment Research on MSN3d
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With ZealandNovo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
Six of nine patients at the highest 740 mg daily ... Roche's oral GLP-1 achieved 6.1% placebo-adjusted weight at the optimum dose in its phase 1 trial, while Viking's VK2735 – like Zepbound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback